thymosin alpha 1 Research: What Happened to People
What have thymosin alpha 1 tests found in people?
When an infection keeps coming back, you may want more than a drug name. From 1977 through 2025, researchers tested thymosin alpha 1 in people with hepatitis, sepsis, HIV, cancer, or weak defenses with age, and they followed both health and blood-test results. Here you can see which results held, which failed, and how sure the answers are.
How might thymosin alpha 1 help your immune system?
Some defense cells have parts on their surface that notice germs. In lab work, thymosin alpha 1 touched four kinds of those parts. The contact helped several kinds of defense cells make more cells and get ready to work [8]. One protein, interleukin 2, carries an order for some defense cells to grow. The drug also raised the cell part that receives interleukin 2.
One dish test used human cells that swallow germs. With thymosin alpha 1, the cells took in and killed a test fungus within 30 minutes [5]. They didn't release two proteins linked to harsh swelling. One was interleukin 6, a protein cells use to pass a swelling message. A dish test can't predict what your whole body will do.
A second dish test used blood from healthy donors. The number of natural killer cells rose 179%. The number of active helper T cells rose 140%, and B cells rose 113% [8]. Another kind of T cell changed in several ways. These cells help find and kill infected cells.
Other lab work found surface changes on cancer cells and infected cells. The changes may help your defenses spot harmful cells [7][8]. This finding came from lab work, not from treatment in a person. It doesn't prove that a person's cancer or infection will get better.
Which paper name means thymosin alpha 1?
TA-1 is a short name used in medical papers. The formal drug name is thymalfasin. A paper may say thymosin alpha-1, Tα1, TA-1, or TA1. Each name means thymosin alpha 1. One sepsis paper uses the short name [2]. Another does too [4]. Many hepatitis papers from China do too [1][15].
Thymosin alpha-1 isn't thymosin beta-4. Both were first found in thymus tissue, but they do different jobs. Researchers tested the beta-4 form, called TB-500 in research sales, for wounds and tissue repair. Thymosin alpha 1 has been tested for the body's defenses. That pairing comes from personal online talk, not a trial that compared groups; no such trial has found that the two drugs act alike.
What did thymosin alpha 1 hepatitis tests find?
The hepatitis B work gives the clearest early result, though some tests were small. A 2001 test gave people 1.6 mg through a shallow skin shot two times each week for 6 months. At the 12-month check, 55.6% with thymosin alpha 1 had a blood result meaning the virus had gone quiet and the body had made defenses against it. The same result appeared in 27.3% with interferon-alpha, an older virus drug, and 3.3% with no care [1]. Thymosin alpha 1 gains kept rising after shots stopped.
A later review joined 8 tests with 583 people. Thymalfasin plus lamivudine, a drug that stops the virus making copies, reached the wanted blood result in 45.1%. Lamivudine alone reached 15.2% [15]. Thymalfasin plus entecavir, another drug that blocks the virus, also did better than entecavir alone in people with liver scars from hepatitis B.
The hepatitis C test was small and came out in 1998. People got interferon-alpha with thymosin alpha 1 or interferon-alpha alone. Blood tests found no virus in 37.1% with both drugs and 18.9% with interferon alone [19]. The paper also gave three liver-test gains: 37.1%, 16.2%, and 2.7%. The summary used here doesn't name all three groups, so those figures can't be matched safely. The two-drug plan also helped some people whose past care had failed [19].
Did thymosin alpha 1 help people with sepsis?
Sepsis can push the body's defenses too hard and then wear them out. Doctors hoped TA-1 could wake the tired cells. Early tests of thymosin alpha 1 looked hopeful. The largest test didn't find fewer deaths.
A sepsis test at several hospitals began in 2013. Very sick people got thymosin alpha 1 at 1.6 mg each day for 7 days, then twice weekly. By the 28-day mark, 26.0% had died, compared with 35.0% without the drug. That was a 9-point gap. Deaths in the hospital were 28.7% and 39.4%. A blood sign that germ-fighting cells were awake improved on days 3 and 7 [2].
A 2016 review joined 19 tests with 1,354 people. It found fewer deaths at the 28-day mark [3]. Blood tests also suggested that several kinds of defense cell were more ready to work. Interleukin 10, a protein that tells cells to calm swelling, rose while a swelling message fell. The papers found no grave harm tied to thymosin alpha 1.
Then a larger test changed the answer. In 2025, it enrolled 1,106 adults at 22 hospitals in China. During this Phase 3 test, no patient or staff member knew who got the drug. The other group got placebo, a look-alike shot with no drug. By the 28-day mark, 23.4% died with TA-1 and 24.1% with placebo [4]. That was no clear gain, which is the result you need when weighing the earlier hope. Smaller checks by age and diabetes can't prove who benefits.
The TA-1 sepsis and COVID-19 findings explain the later COVID-19 reports.
What changed in thymosin alpha 1 COVID-19 tests?
Severe COVID-19 can leave too few germ-fighting cells in the blood. People with very low counts often fare worse. Past work had found more of these cells after thymosin alpha 1, so doctors had a fair reason to test the drug. That reason isn't proof for your case.
A 2023 study gave thymalfasin at 1.6 mg in a shallow skin shot given twice a day. Within 3 days, patients' low cell counts returned to normal at 2.38 times the rate seen with usual care [11]. The paper reported that rate, not the number of people who returned to normal. Among the sickest people on high-flow oxygen, the rate was 3.64 times higher [11]. Helper T cells rose most in people who were less sick at the start.
Several hospital teams in China used thymosin alpha 1 during the 2020-2021 COVID-19 wave. Researchers later looked back at care people had already received. They didn't assign one group to the drug and another group to usual care, so other parts of care could explain the results. A COVID-19 TA-1 study was also placed on a public trial list. These COVID-19 reports on thymosin alpha 1 can't tell you what your result would be.
Could thymalfasin push the immune system too hard?
This drug doesn't shut down your immune system like medicines made to slow it. Thymosin alpha 1 may help weak defenses while calming harsh ones. The calming claim still lacks proof in people.
One blood study included 320 people with psoriatic arthritis, rheumatoid arthritis, or lupus. Their own thymosin alpha 1 levels were lower than those in healthy people [9]. Low thymosin alpha 1 levels can't prove the drug will treat those diseases.
In a dish test, thymosin alpha 1 helped human cells swallow and kill a test fungus. The cells didn't release two proteins linked to swelling, including interleukin 6 [5]. That protein carries a swelling message between cells. Researchers think thymosin alpha 1 may steady the body's defenses, but they haven't proved that effect in all kinds of patients.
What happens to thymosin alpha 1 as the thymus shrinks?
After youth, the thymus gland slowly shrinks. It then makes fewer new T cells and less thymosin alpha 1. This may help explain why vaccines work less well with age and why infections can hit older people harder.
A 2025 review covered tests of thymosin alpha 1 in people, as well as tests in animals and dish-grown cells [14]. Some lab work with thymosin alpha 1 produced more T cells and less harmful swelling. Other tests found less cell damage from waste chemicals made as cells use food and oxygen. Much of this work was not done in people.
The best human test was small and old. In 1989, researchers enrolled 90 older men with an average age of 77.3 years. Neither the men nor the staff knew who got thymosin alpha 1 or placebo, a look-alike shot with no drug. After a flu shot, more men in the drug group had a 4-fold rise in germ-marking blood proteins. Neither group had harm tied to treatment [12]. Men with the weakest first reply gained most.
The thymus and aging section gives the full account.
How strong are the thymosin alpha 1 hepatitis B tests?
The hepatitis B tests led to approved uses abroad. Work from the 1990s and later reviews from China used 1.6 mg in a shallow skin shot, given twice weekly [1][15]. That history tells you what doctors tested. It can't pick a dose for you.
Most tests watched for one blood result. The result meant the hepatitis B virus had gone quiet and the body had made defenses against it. With thymosin alpha 1 alone, 30–55% of people reached that result. Other care or no care reached 3–27% [1]. With lamivudine added, 45.1% reached it, compared with 15.2% on lamivudine alone [15].
The drug doesn't kill the hepatitis B virus by itself. Thymosin alpha 1 may help T cells clear infected liver cells. This may explain why thymosin alpha 1 gains took weeks and kept growing after shots stopped. Virus drugs lower the amount of virus, while TA-1 may help the body's guards find infected cells.